ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

FT839

A development code.

Its studies are mostly in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, led by Fate Therapeutics.

Furthest: phase 2, since Aug 24, 20261 company-led study, 1 open or runningNext primary completion: Oct 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fate Therapeutics11 open or runningphase 2since Aug 24, 2026Aug 24, 2026Oct 2028phase 2 · NCT07800871

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 24, 2026First study: phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisFirst studyNCT07800871 · 446 planned · United States

Ahead

  1. Oct 2028Primary completion: phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07800871

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07800871Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States2RecruitingOct 2028446

How it is read

Names in the registry

  • “FT839”, 1 entry

Codes read as this program: FT839.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.